Effects of Interval Training on Risk Markers for Arrhythmic Death: a Randomized Controlled Trial
Overview
Authors
Affiliations
Objective: To compare the effects of high-intensity interval training versus moderate-intensity continuous training on risk markers of arrhythmic death in patients who recently suffered from an acute coronary syndrome.
Design: Double-blind (patient and evaluator) randomized controlled trial.
Setting: Cardiovascular Prevention and Rehabilitation Centre (EPIC Centre) of the Montreal Heart Institute, Montreal, Canada.
Subjects: A total of 43 patients were randomized following an acute coronary syndrome.
Interventions: Patients were assigned to either high-intensity interval training (n = 18) or isocaloric moderate-intensity continuous training (n = 19), three times a week for a total of 36 sessions.
Main Measures: Heart rate recovery for 5 minutes, heart rate variability for 24 hours, occurrence of ventricular arrhythmias, and QT dispersion were measured before and after the 36 sessions of training.
Results: Among the 43 patients randomized, 6 participants in the high-intensity interval training group stopped training for reasons unrelated to exercise training and were excluded from the analyses. Heart rate recovery improved solely in the high-intensity interval training group, particularly at the end of recovery period ( < 0.05). There were no differences in heart rate variability, occurrence of ventricular arrhythmias, or QT dispersion parameters between the groups at study end.
Conclusion: Despite the lack of power to detect any large difference between the two interventions with respect to risk markers of arrhythmic death, high-intensity interval training appears safe and may be more effective at improving heart rate recovery relative to moderate-intensity continuous training in our patients following acute coronary syndrome.
Costache A, Mastaleru A, Leon M, Roca M, Gavril R, Cosau D Medicina (Kaunas). 2024; 60(11).
PMID: 39597060 PMC: 11596889. DOI: 10.3390/medicina60111875.
Santana L, Monteiro D, Budde H, Ribeiro A, Vieira J, Monteiro E Int J Environ Res Public Health. 2023; 20(9).
PMID: 37174139 PMC: 10177898. DOI: 10.3390/ijerph20095619.
Akowuah E, Mathias A, Bardgett M, Harrison S, Kasim A, Loughran K BMJ Open. 2023; 13(1):e065992.
PMID: 36604134 PMC: 9827267. DOI: 10.1136/bmjopen-2022-065992.
Irisin is an Effector Molecule in Exercise Rehabilitation Following Myocardial Infarction (Review).
Qin S, Tian Z, Boidin M, Buckley B, Thijssen D, Lip G Front Physiol. 2022; 13:935772.
PMID: 35845994 PMC: 9276959. DOI: 10.3389/fphys.2022.935772.
Dun Y, Thomas R, Smith J, Medina-Inojosa J, Squires R, Bonikowske A Cardiovasc Diabetol. 2019; 18(1):104.
PMID: 31412869 PMC: 6694483. DOI: 10.1186/s12933-019-0907-0.